Premium
Pulse methylprednisolone therapy in children with membranoproliferative glomerulonephritis
Author(s) -
EMRE SEVINÇ,
ŞIRIN AYDAN,
ALPAY HARIKA,
TANMAN FAIK,
UYSAL VELI,
NAYIR AHMET,
BILGE ILMAY
Publication year - 1995
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/j.1442-200x.1995.tb03390.x
Subject(s) - medicine , membranoproliferative glomerulonephritis , methylprednisolone , glomerulonephritis , kidney
The effects of pulse methylprednisolone (PM) therapy were studied in 15 patients (aged 3–14 years) with biopsy proven membranoproliferative glomerulonephritis (MPGN). Patients were treated with intravenous PM 30 mg/kg (max 1 g) given over 30 min every other day for a mean of 9.8 days (3–15 days). Oral prednisolone therapy was continued at a dose of 1 mg/kg/24 h for 1 month and subsequently tapered off the following month. Eight patients had hematuria and six had medically controlled hypertension. Serum C 3 levels were low in 11 patients and all of the patients had proteinuria. Following PM therapy proteinuria was significantly reduced from 2602.9 ± 1852.5 mg/24 h to 1871.2 ± 2090.8 mg/24 h ( P < 0.05) and at final evaluation, proteinuria was 774.33 ± 1225.67 mg/24 h which was significantly lower than pre‐ and post‐PM therapy values ( P < 0.05). Serum creatinine levels were high in five patients before PM therapy and remained high in one of the patients who progressed to end‐stage renal failure. After PM therapy, high serum creatinine levels normalized in three patients and was reduced, but still above normal, in one. One patient, with initially normal serum creatinine, had elevated levels afterwards. Nine of the patients were considered responsive and six non‐responsive according to our tentatively defined criteria. Mean follow‐up period was 27.4 ± 24.1 months (6–84 months). Three patients were lost for follow‐up, and 12 were re‐evaluated. At final evaluation, all of the patients except one with end‐stage renal failure had normal creatinine levels. There was no correlation between the clinical and laboratory features at onset and the outcome of the disease in the responder or non‐responder patients. Results of our study show that PM therapy reduced proteinuria and may affect renal function positively in patients with MPGN. However, a prospective controlled study with repeat biopsies is required to draw a conclusion.